The impact of extended release exenatide as adjuvant therapy on hemoglobin A1C, weight, and total daily dose of insulin in patients with type 2 diabetes mellitus using U-500 insulin

In patients treated with regular U-500 insulin, adjuvant exenatide ER therapy showed no significant improvement in HbA1C, but did show modest weight loss as well as decreased insulin requirements to achieve a HbA1C that was comparable to baseline.